KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2022;36(1):24-28 / www.klinickafarmakologie.cz 28 HLAVNÍ TÉMA Antifibrinolytika a jejich použití v kardiochirurgii LITERATURA 1. Penka M. Fyziologie krevního srážení. In: Penka M, Penka I, Gumulec J et al. Krvácení. Praha: Grada;2014. p. 27-31. 2. Levy JH. Antifibrinolytic therapy. New data and new concepts. Lancet 2010;376:3-4. 3. Hájek R, Zezula R, Fluger I, et al. Význam tromboelastografie pro monitorování hemostázy v kardiochirurgii. Interv Akut Kardiol 2005;4(4):224-228. 4. Hájek R, Růžičková J, Gwozdziewicz M, et al. Hodnocení funkce trombocytů během mimotělního oběhu pomocí tromboelastografie. Cardiol 2006;15(2):78-88. 5. Royston D. Haemostasis management. In: Alston RP, Myles PS, Ranucci M et. al. Oxford textbook of cardiothoracic anaesthesia. Oxford: Oxford Univesity Press; 2015. p. 181-191. 6. Koster A, Faraoni D, Levy JH. Antifibrinolytic therapy for cardiacsurgery: an update. Anesthesiology. 2015;123:214-212. 7. Primm AN. Fibrinolysis, antifibrinolytic agents and perioperative consideration. In: Scher CS, Kaye AD, Liu H et al. Essentials of bloodproduct management in anesthesia practice . Cham: Springer Nature; 2021. p. 37-51. 8. Faraoni D. Fibrinolytic system. In: von Heymann C, Boer C. Patient blood management in cardiac surgery. Cham: Springer Nature; 2019. p. 107-116. 9. Royston D, Taylor KM, Bidstrup BP, et al. Effect of aprotinin on need for bloodtransfusion after repeat open heart surgery. Lancet 1987;330:1289-1291. 10. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann ThoracSurg 2011;91(3):944-982. 11. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogenic bloodtransfusion. Cochrane Database SysRev.2007;1:CD001886. 12. Mangano DT, Tudor IC, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365. 13. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion. 2006;46:327-338. 14. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319-2331. 15. Maybohm P, Herrmann E, Nierhoff J, et al. Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patiens compared to tranexamic acid or ε-aminocapronic acid – a meta-analysis of randomised and observational trials over 30,000 patients. PloSOne, 2013; 8,3, p.e58009. 16. European Society of Anaesthesiology Task Force Report son Place of Aprotinin in Clinical Anaesthesia. Aprotinin, is it time to reconsider? Eur J Anaesthesiol. 2015;32:591-595. 17. Ortmann E, Besse MV, Klein A. Antifibrinolytic agents in current anesthesiologic practice. BJA. 2013;111(4):549563. 18. Sigaut S, Tremey B, Outtara A, et al. Comparison of two doses of tranexamic acid in patiens undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology. 2014;120:590-600. 19. Boer C, Meesters MI, Milojevic M, et al. 2017 EACTS/EACTA guidelines on patient blood management for adult cardiac surgery. J CardiothoracVascAnesth. 2017;25:1-34. 20. Myles PS, Smith JA, Forbes A, et al. Tranexamic acid in patiens undergoing coronary-artery surgery. N Engl J Med. 2017;376:136-148. 21. Koster A, Borgermann J, Zittermann A, et al. Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome. BJA. 2013;110(1):34-40. 22. Kratzer S, Irl H, Mattusch C, et al. Tranexamic acid impairs gamma-aminobutyric acid receptor type A – mediated synaptic transmission in the murine amygdala: a potential mechanism for drug-induced seizures? Anesthesiology. 2014;120:639-649. 23. Lecker I, Wang DS, Romaschin AD, et al. Tranexamic acid concentrations associated withhuman seizures inhibit glycin receptors. J Clin Invest. 2012;122:4651-4666. 24. Jerath A, Yang QI, Pang KS, et al. Tranexamic acid dosing for cardiac surgical patiens with chronic renal dysfunction: a new dosing regimen. AnestAnalg. 2018;127:1323-1332. 25. Peralta R,Thani H,Rizoli S. Coagulopathy in the surgicalpatient: trauma-induced and drug-induced coagulopathies. Current Opinion in Critical Care. 2019;25(6):668-674. 26. Gall LS, Davenport RA. Fibrinolysis and antifibrinolytic treatment in the trauma patient. Current Opinion in Anaesthesiology. 2018;31(2):227-233. 27. Perrault LP, Moukhariq FZ. Fibrin sealants in cardiac surgery. In: Raja SG. Cardiac surgery- a complete guide. Cham: Springer nature; 2020. p. 119-127. PRAGUE SYMPOSIUM 2022 Polypharmacy and ageing – highly-individualized, person-centered care October 19–21, 2022 Prague, Czech Republic Congress & Wellness Hotel Olšanka
RkJQdWJsaXNoZXIy NDA4Mjc=